Hilltop Holdings Inc. Fibrogen Inc Transaction History

Hilltop Holdings Inc.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$31.0 - $55.72 $1.11 Million - $1.99 Million	-35,690 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$37.09 - $48.97 $61,198 - $80,800	1,650 Added 4.85%	35,690 $1.32 Million
Q3 2020 Nov 16, 2020	SELL	$40.47 - $45.5 $60,705 - $68,250	-1,500 Reduced 4.22%	34,040 $1.4 Million
Q2 2020 Aug 14, 2020	SELL	$32.57 - $42.83 $73,282 - $96,367	-2,250 Reduced 5.95%	35,540 $1.44 Million
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $124,655 - $245,886	-5,350 Reduced 12.4%	37,790 $1.31 Million
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $14,523 - $20,185	-420 Reduced 0.96%	43,140 $1.85 Million
Q3 2019 Nov 14, 2019	SELL	$36.98 - $48.45 $194,144 - $254,362	-5,250 Reduced 10.76%	43,560 $1.61 Million
Q2 2019 Aug 14, 2019	BUY	$35.13 - $55.53 $172,137 - $272,097	4,900 Added 11.16%	48,810 $2.21 Million
Q1 2019 May 15, 2019	BUY	$42.83 - $59.91 $8,566 - $11,982	200 Added 0.46%	43,910 $2.39 Million
Q4 2018 Feb 14, 2019	SELL	$37.97 - $60.16 $383,497 - $607,616	-10,100 Reduced 18.77%	43,710 $2.02 Million
Q3 2018 Nov 14, 2018	SELL	$56.3 - $67.25 $74,879 - $89,442	-1,330 Reduced 2.41%	53,810 $3.27 Million
Q2 2018 Aug 14, 2018	BUY	$44.9 - $64.95 $68,697 - $99,373	1,530 Added 2.85%	55,140 $3.45 Million
Q1 2018 May 15, 2018	BUY	$45.35 - $61.65 $795,212 - $1.08 Million	17,535 Added 48.61%	53,610 $2.48 Million
Q4 2017 Feb 14, 2018	SELL	$41.95 - $60.1 $184,580 - $264,440	-4,400 Reduced 10.87%	36,075 $1.71 Million
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $1.35 Million - $2.18 Million	40,475	40,475 $2.18 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Hilltop Holdings Inc., based on Form 13F filings with the SEC.

Stay updated on Hilltop Holdings Inc. with notifications on news.